THE US Food and Drug Administration (FDA) approved Ingrezza (valbenazine) capsules, the first product the Administration has approved for the treatment of adults with tardive dyskinesia.
The above article was sent to subscribers in Pharmacy Daily's issue from 13 Apr 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 13 Apr 17